New vaccine aims to fight childhood brain tumors without surgery
NCT ID NCT02358187
First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This phase 2 trial tests a vaccine made from glioma antigen peptides combined with an immune booster (Poly-ICLC) in 25 children with recurrent low-grade gliomas that cannot be removed by surgery. The goal is to see if the vaccine can shrink tumors or keep them stable. Children who respond well may continue vaccinations for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Pittsburgh of UPMC
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glioma antigen peptides with Poly-ICLC
What this could lead to
If it works, this could offer a new treatment option for children with hard-to-treat low-grade gliomas, potentially shrinking tumors or keeping them from growing.
What could go wrong
This is a small, early-phase trial with only 25 children. The vaccine may not work for everyone, and side effects like fever or injection reactions are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.